文献速递肝胆胰外科

血清DUPAN-2可作为胰腺癌CA19-9不分泌者的替代生物标志物

Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer.
PubMed 文献 · Ann Surg · 2022-01-25

本研究纳入2005至2019年连续接受胰腺切除术的984例胰腺癌患者,其中CA19-9不分泌者94例(9.6%)。不分泌者中DUPAN-2>2000U/mL为独立预后不良因素(HR 2.53,P=0.010),其预后影响与分泌者中CA19-9>500U/mL相当(HR 2.08 vs 1.89)。

要点

  • CA19-9不分泌胰腺癌患者占切除病例的9.6%。
  • 不分泌者中DUPAN-2>2000U/mL是独立预后不良因素(HR 2.53)。
  • 该阈值预后影响与分泌者CA19-9>500U/mL相近(HR 2.08 vs 1.89)。

核心结论

  • CA19-9不分泌者中DUPAN-2>2000U/mL是不良预后因素,对应分泌者中CA19-9>500U/mL的预后意义。
  • 该结果揭示了传统上被认为预后较好的不分泌者中实际存在预后不良的亚群。

研究设计与样本

  • 回顾性评估2005至2019年连续接受胰腺切除术的胰腺癌患者。
  • 共纳入984例切除患者,按CA19-9≤或>2.0U/mL分为不分泌者(94例,9.6%)和分泌者(890例,90.4%)。

主要发现

  • 两组基线特征除DUPAN-2水平外无统计学差异(720 vs 100U/mL,P<0.001)。
  • 两组切除后生存曲线相似(29.4个月 vs 31.3个月,P=0.900)。
  • 不分泌者中DUPAN-2>2000U/mL与分泌者中CA19-9>500U/mL的生存曲线几乎等效(HR 2.08 vs 1.89)。
  • 多因素分析中DUPAN-2>2000U/mL为切除后独立预后因素(HR 2.53,P=0.010)。

关键数值与推荐

  • CA19-9不分泌定义为CA19-9≤2.0U/mL,分泌定义为CA19-9>2.0U/mL。
  • DUPAN-2>2000U/mL为CA19-9不分泌者的预后不良阈值。
  • CA19-9>500U/mL为CA19-9分泌者的预后不良阈值及增强新辅助治疗指征。

临床怎么用

  • 对CA19-9不分泌的胰腺癌切除患者,可检测血清DUPAN-2以识别预后不良亚群。
  • DUPAN-2>2000U/mL的不分泌者预后与CA19-9>500U/mL的分泌者相当,后者为增强新辅助治疗指征。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study investigates the use of serum DUPAN-2 in predicting the PC progression in CA19-9 nonsecretors. BACKGROUND: Although we previously reported that serum CA19-9 >500U/ mL is a poor prognostic factor and an indication for enhanced neoadjuvant treatment, there is not a biomarker surrogate that equivalently predicts prognosis for CA19-9 nonsecretors. METHODS: We evaluated consecutive PC patients who underwent pancreatectomy from 2005 to 2019. All patients were categorized as either nonsecretor or secretor (CA19-9 ≤ or >2.0U/mL). RESULTS: Of the 984 resected PC patients, 94 (9.6%) were nonsecretors and 890 (90.4%) were secretors. The baseline characteristics were not statistically different between the 2 groups except for the level of DUPAN-2 (720 vs. 100U/mL, P < 0.001). Survival curves after resection were similar between the 2 groups (29.4 months vs. 31.3 months, P = 0.900). Survival curves of patients with DUPAN-2 >2000U/mL in the nonsecretors and patients with CA19-9 >500U/mL in the secretors were nearly equivalent as well (hazard ratio 2.08 vs. 1.89). In the multivariate analysis, DUPAN-2 >2000U/mL (hazard ratio 2.53, P = 0.010) was identified as independent prognostic factor after resection. CONCLUSION: DUPAN-2 >2000U/mL in CA19-9 nonsecretors can be an unfavorable factor that corresponds to CA19-9 >500U/mL in CA19-9 secretors which is an indicator for enhanced neoadjuvant treatment. The current results shed light on the subset of nonsecretors with poor prognosis that were traditionally categorized in a group with a more favorable prognosis group.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Omiya K, Oba A, Inoue Y, et al. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Ann Surg. 2022. PMID: 35081567. doi:10.1097/SLA.0000000000005395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。